vs
Life Time Group Holdings, Inc.（LTH）とRevvity（RVTY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Revvityの直近四半期売上が大きい（$772.1M vs $745.1M、Life Time Group Holdings, Inc.の約1.0倍）。Life Time Group Holdings, Inc.の純利益率が高く（16.5% vs 12.7%、差は3.8%）。Life Time Group Holdings, Inc.の前年同期比売上増加率が高い（12.3% vs 5.9%）。Revvityの直近四半期フリーキャッシュフローが多い（$161.8M vs $-64.6M）。過去8四半期でLife Time Group Holdings, Inc.の売上複合成長率が高い（11.7% vs 9.0%）
Life Time Group Holdings, Inc.は米国全域で高級スポーツ・フィットネス・ウェルネス施設を運営する企業です。最新鋭のジム設備、グループエクササイズ、パーソナルトレーニング、スパ、栄養指導、子ども向けプログラム、コワーキングスペースなど、健康的なライフスタイルを求める人々に総合的なサービスを提供しています。
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
LTH vs RVTY — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $745.1M | $772.1M |
| 純利益 | $123.0M | $98.4M |
| 粗利率 | 49.1% | — |
| 営業利益率 | 17.4% | 14.5% |
| 純利益率 | 16.5% | 12.7% |
| 売上前年比 | 12.3% | 5.9% |
| 純利益前年比 | 231.0% | 3.9% |
| EPS（希薄化後） | $0.55 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $745.1M | $772.1M | ||
| Q3 25 | $782.6M | $698.9M | ||
| Q2 25 | $761.5M | $720.3M | ||
| Q1 25 | $706.0M | $664.8M | ||
| Q4 24 | $663.3M | $729.4M | ||
| Q3 24 | $693.2M | $684.0M | ||
| Q2 24 | $667.8M | $691.7M | ||
| Q1 24 | $596.7M | $649.9M |
| Q4 25 | $123.0M | $98.4M | ||
| Q3 25 | $102.4M | $46.7M | ||
| Q2 25 | $72.1M | $53.9M | ||
| Q1 25 | $76.1M | $42.2M | ||
| Q4 24 | $37.2M | $94.6M | ||
| Q3 24 | $41.4M | $94.4M | ||
| Q2 24 | $52.8M | $55.4M | ||
| Q1 24 | $24.9M | $26.0M |
| Q4 25 | 49.1% | — | ||
| Q3 25 | 47.1% | 53.6% | ||
| Q2 25 | 47.0% | 54.5% | ||
| Q1 25 | 47.5% | 56.5% | ||
| Q4 24 | 48.2% | — | ||
| Q3 24 | 46.5% | 56.3% | ||
| Q2 24 | 46.8% | 55.7% | ||
| Q1 24 | 46.1% | 54.6% |
| Q4 25 | 17.4% | 14.5% | ||
| Q3 25 | 17.3% | 11.7% | ||
| Q2 25 | 14.2% | 12.6% | ||
| Q1 25 | 15.2% | 10.9% | ||
| Q4 24 | 13.1% | 16.3% | ||
| Q3 24 | 13.5% | 14.3% | ||
| Q2 24 | 15.7% | 12.4% | ||
| Q1 24 | 12.1% | 6.8% |
| Q4 25 | 16.5% | 12.7% | ||
| Q3 25 | 13.1% | 6.7% | ||
| Q2 25 | 9.5% | 7.5% | ||
| Q1 25 | 10.8% | 6.4% | ||
| Q4 24 | 5.6% | 13.0% | ||
| Q3 24 | 6.0% | 13.8% | ||
| Q2 24 | 7.9% | 8.0% | ||
| Q1 24 | 4.2% | 4.0% |
| Q4 25 | $0.55 | $0.86 | ||
| Q3 25 | $0.45 | $0.40 | ||
| Q2 25 | $0.32 | $0.46 | ||
| Q1 25 | $0.34 | $0.35 | ||
| Q4 24 | $0.17 | $0.77 | ||
| Q3 24 | $0.19 | $0.77 | ||
| Q2 24 | $0.26 | $0.45 | ||
| Q1 24 | $0.12 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $204.8M | $919.9M |
| 総負債低いほど良い | $1.5B | — |
| 株主資本純資産 | $3.1B | $7.3B |
| 総資産 | $8.0B | $12.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.48× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $204.8M | $919.9M | ||
| Q3 25 | $218.9M | $931.4M | ||
| Q2 25 | $175.5M | $991.8M | ||
| Q1 25 | $59.0M | $1.1B | ||
| Q4 24 | $10.9M | $1.2B | ||
| Q3 24 | $120.9M | $1.2B | ||
| Q2 24 | $34.5M | $2.0B | ||
| Q1 24 | $18.6M | $1.7B |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.8B | — | ||
| Q1 24 | $2.0B | — |
| Q4 25 | $3.1B | $7.3B | ||
| Q3 25 | $3.0B | $7.4B | ||
| Q2 25 | $2.9B | $7.6B | ||
| Q1 25 | $2.7B | $7.6B | ||
| Q4 24 | $2.6B | $7.7B | ||
| Q3 24 | $2.6B | $7.9B | ||
| Q2 24 | $2.4B | $7.9B | ||
| Q1 24 | $2.3B | $7.8B |
| Q4 25 | $8.0B | $12.2B | ||
| Q3 25 | $7.8B | $12.1B | ||
| Q2 25 | $7.6B | $12.4B | ||
| Q1 25 | $7.3B | $12.4B | ||
| Q4 24 | $7.2B | $12.4B | ||
| Q3 24 | $7.2B | $12.8B | ||
| Q2 24 | $7.1B | $13.4B | ||
| Q1 24 | $7.1B | $13.4B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.53× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.59× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.87× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $239.9M | $182.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $-64.6M | $161.8M |
| FCFマージンFCF / 売上 | -8.7% | 21.0% |
| 設備投資強度設備投資 / 売上 | 40.9% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 1.95× | 1.85× |
| 直近12ヶ月FCF直近4四半期 | $-21.0M | $509.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $239.9M | $182.0M | ||
| Q3 25 | $251.1M | $138.5M | ||
| Q2 25 | $195.7M | $134.3M | ||
| Q1 25 | $183.9M | $128.2M | ||
| Q4 24 | $163.1M | $174.2M | ||
| Q3 24 | $151.1M | $147.9M | ||
| Q2 24 | $170.4M | $158.6M | ||
| Q1 24 | $90.4M | $147.6M |
| Q4 25 | $-64.6M | $161.8M | ||
| Q3 25 | $28.6M | $120.0M | ||
| Q2 25 | $-26.3M | $115.5M | ||
| Q1 25 | $41.4M | $112.2M | ||
| Q4 24 | $26.8M | $149.8M | ||
| Q3 24 | $64.0M | $125.6M | ||
| Q2 24 | $26.1M | $136.6M | ||
| Q1 24 | $-66.4M | $129.7M |
| Q4 25 | -8.7% | 21.0% | ||
| Q3 25 | 3.7% | 17.2% | ||
| Q2 25 | -3.5% | 16.0% | ||
| Q1 25 | 5.9% | 16.9% | ||
| Q4 24 | 4.0% | 20.5% | ||
| Q3 24 | 9.2% | 18.4% | ||
| Q2 24 | 3.9% | 19.7% | ||
| Q1 24 | -11.1% | 20.0% |
| Q4 25 | 40.9% | 2.6% | ||
| Q3 25 | 28.4% | 2.6% | ||
| Q2 25 | 29.2% | 2.6% | ||
| Q1 25 | 20.2% | 2.4% | ||
| Q4 24 | 20.6% | 3.4% | ||
| Q3 24 | 12.6% | 3.3% | ||
| Q2 24 | 21.6% | 3.2% | ||
| Q1 24 | 26.3% | 2.7% |
| Q4 25 | 1.95× | 1.85× | ||
| Q3 25 | 2.45× | 2.97× | ||
| Q2 25 | 2.71× | 2.49× | ||
| Q1 25 | 2.41× | 3.03× | ||
| Q4 24 | 4.39× | 1.84× | ||
| Q3 24 | 3.65× | 1.57× | ||
| Q2 24 | 3.23× | 2.87× | ||
| Q1 24 | 3.63× | 5.67× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
LTH
| Membership | $535.1M | 72% |
| In Center | $191.2M | 26% |
| Other | $18.8M | 3% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
